Krka, d. d., a generic pharmaceutical company, (KRK) Fair Value & Analysis
Healthcare · PL · Market cap 35.3B PLN
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 21 days ago
Fair value updated Jul 17, 2026, revised from 272.37 PLN to 1,134 PLN (+316.4%) since Jun 24, 2026. Share price −0.5% over the past month.
A strong business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from 803.25 PLN (bear) to 1,415 PLN (bull), base 1,134 PLN. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 79/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range 316.08 PLN – 1,178 PLN · fair‑value band 803.25 PLN – 1,415 PLN · the 1,122 PLN price screens below the 1,134 PLN fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Krka, d. d., a generic pharmaceutical company, (KRK) currently trades at 1,122 PLN, while our model-based Fair Value estimate is 1,134 PLN, implying the stock looks roughly 1.1% fairly valued today. We read business quality at 79/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Krka, d. d., a generic pharmaceutical company, generated revenue of 2.1B PLN at a net margin of 17.8%. Revenue grew 8.4% year over year. It earns a return on equity of 15.2%. The balance sheet holds a net cash position of 330M PLN. Fundamentals as of Jul 17, 2026
Our scenario range runs from 803.25 PLN (bear case) to 1,415 PLN (bull case); at 1,122 PLN, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 50% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 1%, KRK screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (1,124 PLN) versus Asset-Based (240.08 PLN). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 76 · Market factors (momentum, volatility) 74
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
Full company description
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabolism, and other therapeutic areas, as well as analgesics, vitamins, minerals, and vasoprotectives. In addition, the company offers animal health products, including antiparasitics, antimicrobials, and other products. Further, it provides health resort and tourist services. The company was founded in 1954 and is based in Novo Mesto, Slovenia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Krka, d. d., a generic pharmaceutical company, reported revenue of 2.0B PLN in FY2025 versus 1.6B PLN in FY2021, a compound +6.9%/yr. Reported net income was 403M PLN in FY2025, compounding +6.9%/yr from FY2021.
Watch KRK: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Krka, d. d., a generic pharmaceutical company, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Krka, d. d., a generic pharmaceutical company, (KRK) overvalued or undervalued?
What is the fair value of KRK?
What is the quality score of KRK?
What is the revenue of Krka, d. d., a generic pharmaceutical company, (KRK)?
What is the net profit margin of KRK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Krka, d. d., a generic pharmaceutical company, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.